Core Points - The company issued a total of 5,412,932 new shares to board member Annika Olsson as part of her board remuneration [1][2] - An additional 69 shares were issued to an employee at a price of NOK 0.01 per share, related to a share consolidation of 100-to-1 [3] - Following these issuances, the company's share capital will amount to NOK 47,364,256, divided into 4,736,425,600 registered shares with a nominal value of NOK 0.01 [4] Company Overview - IDEX Biometrics ASA is a global technology leader in fingerprint biometrics, providing authentication solutions for payments, access control, and digital identity [4] - The company's biometric solutions are built on patented sensor technologies and target card-based applications for payments and digital authentication [4] - IDEX partners with leading card manufacturers and technology companies to bring its solutions to market [4]

Group 1 - The issuance of new shares in Kaldvik AS was announced on 22 April 2025 [1] - Heimstø AS and Ósval ehf., associates of a primary insider, have completed transactions in Kaldvik AS shares [1] - The transactions are detailed in attached notifications of trading [1] Group 2 - The information is subject to disclosure requirements under the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian Securities Trading Act Section 5-12 [2] - Attachments include notifications related to the transactions by Heimstø AS and Ósval ehf [3]

Core Viewpoint - Ningbo Construction Co., Ltd. is in the process of acquiring 100% equity of Ningbo Transportation Engineering Construction Group Co., Ltd. through a share issuance, with the review process by the Shanghai Stock Exchange being resumed after necessary updates and submissions [2][3]. Group 1 - The company received a notification from the Shanghai Stock Exchange on December 31, 2024, regarding the acceptance of its application for the share issuance to purchase assets [2]. - On January 10, 2025, the company received an inquiry letter from the Shanghai Stock Exchange regarding the asset purchase and related transactions [2]. - The company completed the necessary updates and submitted the application for resuming the review process to the Shanghai Stock Exchange, which was approved on May 19, 2025 [3]. Group 2 - The transaction is subject to approval by the Shanghai Stock Exchange and registration by the China Securities Regulatory Commission, indicating uncertainty regarding the completion of the transaction [3]. - The company will fulfill its information disclosure obligations in accordance with relevant regulations based on the progress of the transaction [3].

RAPALA VMC CORPORATION, Decisions of general meeting, May 8, 2025 at 4:00 p.m. EET The Annual General Meeting (AGM) of Rapala VMC Corporation has on 8 May 2025 adopted the financial statement of the financial year 2024 and discharged the members of the Board of Directors, the CEO and the deputy CEO from liability for the financial year that ended on 31 December 2024. The AGM approved the remuneration report for governing bodies for the financial year 2024. The AGM approved the Board of Director’s proposal, ...

KH Group PlcStock exchange release 6 May 2025 at 6:15 pm EEST Decisions of KH Group’s Annual General Meeting and the constitutive meeting of the Board of Directors KH Group Plc’s Annual General Meeting was held on 6 May 2025 at Sanomatalo, Flik Event Studio Eliel, at the address Töölönlahdenkatu 2, 00100 Helsinki, Finland. The Annual General Meeting supported all the proposals included in the notice of the Annual General Meeting. The General Meeting adopted the financial statements for the financial period ...

Core Points - Pharma Equity Group A/S held its Annual General Meeting on April 16, 2025, where various proposals were discussed and adopted [1][6] Group 1: Board of Directors' Report - The former CEO, Thomas Kaas Selsø, presented the Board's report on the Company's activities over the past year, addressing shareholder questions regarding the Market Maker agreement with Danske Bank and the potential delisting from Nasdaq Copenhagen [3][4] - Shareholders expressed concerns about the declining share price, attributing it to large shareholders selling their shares, while also acknowledging the Company's successful financing in 2024 and positive research results [4][5] Group 2: Financial Proposals - The audited 2023 annual report was presented, and the discharge of the Board and Executive Management was proposed, with no objections raised from shareholders [8][11] - The expected revenue for the current financial year was projected at DKK 11 million, based on valuations prepared by Baker Tilly and reviewed by Danske Bank [9] - Outstanding convertible loans were confirmed to total approximately DKK 13 million [10] Group 3: Remuneration and Board Elections - The remuneration for the Board of Directors for the 2025 financial year was proposed, with the Chairman receiving DKK 350,000 and Board members receiving DKK 150,000 [14] - All current Board members were re-elected, and two new members, Troels Peter Troelsen and Charlotte Pahl, were elected [16][17] - BDO Statsautoriseret Revisionsaktieselskab was re-elected as the Company's auditor [18] Group 4: Proposals and Authorizations - Three proposals from the Board were discussed, requiring different majorities for adoption, and all were approved without objections [19][20] - The chairman was authorized to file the adopted resolutions with the Danish Business Authority [21] Group 5: Company Overview - Pharma Equity Group A/S is dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S, with a focus on healthcare and innovative medical solutions [23][24]

Dovre Group Plc Stock Exchange Release April 29, 2025, at 5:45 pm DECISIONS OF THE ANNUAL GENERAL MEETING OF DOVRE GROUP PLC Dovre Group Plc’s Annual General Meeting held today on April 29, 2025, adopted the financial statements and consolidated financial statements for 2024 and discharged the members of the Board of Directors and the CEO from liability for the financial year ending on December 31, 2024. The Annual General Meeting also decided on the composition and remuneration of the Board of Directors, ...